En levant les yeux vers le ciel nocturne dans la nuit de lundi à mardi, peut-être avez-vous eu la chance d’apercevoir une brève mais intense traînée de lumière. Mais de quoi s’agissait-il ?

In an extremely odd case, a single 79-year-old patient was granted early access to Eli Lilly's powerful, still-experimental obesity drug retatrutide through the Food and Drug Administration's "compassionate use" program—raising immediate questions if that sole patient is President Donald Trump, according to a report by Stat News.

Lilly's retatrutide is a highly anticipated next-generation obesity drug that targets GIP and glucagon hormones in addition to GLP-1. It is currently in late-stage trials to treat obesity, diabetes, sleep apnea, and other conditions. Data from a Phase 3 trial that Lilly released in May indicates that patients with obesity (but without diabetes) who took the drug for 80 weeks lost 28 percent of their weight, an amount comparable to bariatric surgery.

Millions of Americans with obesity are eager to get the drug, with options being limited so far to enrolling in a clinical trial or trying to obtain it by dodgy methods.

Read full article

Comments

© Getty | Aaron Schwartz

Face aux canicules extrêmes qui font suffoquer l’Hexagone, brancher un ventilateur est une évidence. Pourtant, lorsque les températures dépassent certains seuils, son efficacité diminue fortement et il peut même devenir contre-productif. Bien que le ventilateur puisse apporter un soulagement...

The interstellar comet 3I/ATLAS carries a chemical fingerprint unlike anything in our Solar System, and it may have formed 10 to 12 billion years ago, before our Sun even existed, according to two papers published in the journal Nature.

The post Interstellar Comet 3I/ATLAS Formed Up To 12 Billion Years Ago, New Observations Suggest appeared first on Sci.News: Breaking Science News.